Boundless Bio Inc. (BOLD) AI Stock Analysis

• Market Cap: $25.74M
• Dividend Yield: N/A
• Average Volume (3M): 72.34K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.89
• Revenue Growth: N/A
• EPS Growth: -10.95%
• Country: US
• Employees: 64
• Sector: General
• Sector Strength: N/A
• Industry: Biotechnology
• EPS (TTM): -0.70
• Shares Outstanding: 22,385,610
• 10 Day Avg. Volume: 67,257
• 30 Day Avg. Volume: 72,340
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: -2.14
• Enterprise Value/Revenue: -52.14
• Enterprise Value/Gross Profit: 149.62
• Enterprise Value/Ebitda: 0.90
• 1Y Price Target: $3.50
• Price Target Upside: 204.35% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 40 Underperform
• Price Target: ―

Boundless Bio Inc. scores low due to its challenging financial situation with no revenue and high operational costs, despite some improvements in equity and liquidity. The technical analysis suggests possible short-term recovery potential, but the negative valuation metrics underscore the speculative nature of the stock. Investors should be cautious, as future gains depend heavily on successful product commercialization.

Positive Factors

Innovative Therapies

The company's focus on innovative cancer therapies targeting ecDNA positions it as a leader in cutting-edge cancer treatment, potentially transforming patient outcomes and establishing a competitive advantage in the biopharmaceutical sector.

Improved Equity Position

Improved equity position enhances financial stability, providing a stronger foundation for future growth and potentially attracting more investment, which is crucial for a biotech firm in its developmental stage.

Increased Liquidity

Increased liquidity ensures the company can sustain operations and invest in R&D, which is vital for advancing clinical trials and achieving long-term commercialization goals in the biotech industry.

Negative Factors

No Revenue

The absence of revenue highlights the company's reliance on external funding and underscores the risk associated with its early-stage development, making financial sustainability dependent on future product commercialization.

High Operational Costs

Persistent high operational costs without offsetting revenue can strain financial resources, necessitating efficient cost management and successful product development to achieve profitability.

Negative Cash Flow

Negative cash flow indicates challenges in funding operations internally, increasing dependence on external financing and highlighting the urgency of achieving revenue generation through successful product launches.

Boundless Bio Inc. Business Overview & Revenue Model

Company Description

Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California.

How the Company Makes Money

Boundless Bio Inc. generates revenue primarily through the development and commercialization of its proprietary therapies targeting ecDNA in cancer cells. The company may receive funding through partnerships, collaborations, and licensing agreements with other pharmaceutical companies, which provide financial support for its research and development activities. Additionally, revenue could be derived from milestone payments and royalties related to the successful advancement and commercialization of its therapeutic products. Public and private funding rounds may also contribute to its financial resources, enabling ongoing research and clinical trials.

Boundless Bio Inc. Financial Statement Overview

Summary

Boundless Bio Inc. is facing significant financial challenges typical of a biotechnology start-up, with no revenue and high operational costs leading to continued losses. While there are improvements in equity and liquidity, the company heavily relies on external financing for operations. Future stability depends on successful product commercialization and operational efficiency improvements.

Income Statement

Boundless Bio Inc. has consistently reported zero revenue over the past years, indicating no sales or commercialized products. The net income has been negative, showing persistent losses, with net losses increasing year-over-year. The negative EBIT and EBITDA margins further highlight operational challenges and high costs relative to non-existent revenues.

Balance Sheet

The company has shown improvement in its equity position, moving from negative equity to a positive equity situation, which indicates better financial stability. However, the debt-to-equity ratio improvement is due to increasing equity rather than reducing liabilities. The company's cash and short-term investments have increased, providing liquidity, but liabilities remain substantial.

Cash Flow

Operating cash flow remains negative, reflecting the company's inability to generate cash from its core operations. The free cash flow is also negative, indicating that the company is not generating enough cash to cover its capital expenditures. However, significant financing activities suggest reliance on external funding to sustain operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2018
Income Statement
Total Revenue	1.06M	0.00	0.00	0.00	0.00	0.00
Gross Profit	-368.00K	-1.09M	-957.00K	-942.00K	-682.00K	0.00
EBITDA	-61.23M	-64.28M	-48.48M	-45.53M	-24.62M	-121.36M
Net Income	-64.39M	-65.36M	-49.43M	-45.90M	-25.21M	-128.82M
Balance Sheet
Total Assets	179.45M	206.41M	129.89M	76.83M	113.72M	472.56M
Cash, Cash Equivalents and Short-Term Investments	127.15M	152.11M	120.75M	66.72M	73.03M	414.31M
Total Debt	49.51M	47.63M	2.19M	5.18M	377.00K	7.07M
Total Liabilities	56.76M	55.77M	256.98M	158.53M	151.91M	29.80M
Stockholders Equity	122.69M	150.64M	-127.08M	-81.70M	-38.19M	442.75M
Cash Flow
Free Cash Flow	-56.24M	-63.38M	-47.49M	-40.66M	-25.28M	-119.59M
Operating Cash Flow	-55.19M	-60.84M	-46.85M	-39.60M	-23.25M	-107.98M
Investing Cash Flow	38.30M	-26.10M	-38.26M	16.13M	-59.28M	-185.05M
Financing Cash Flow	217.00K	89.82M	97.90M	126.00K	105.53M	398.46M

Boundless Bio Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.15
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BOLD, the sentiment is Negative. The current price of 1.15 is above the 20-day moving average (MA) of 1.15, below the 50-day MA of 1.16, and below the 200-day MA of 1.68, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 49.89 is Neutral, neither overbought nor oversold. The STOCH value of 80.95 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BOLD.

Boundless Bio Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	55 Neutral	$6.59B	3.85	-15.92%	6.10%	10.91%	7.18%
PLUR	49 Neutral	$38.67M	―	-1205.58%	―	203.23%	13.57%
ALGS	47 Neutral	$62.74M	―	-87.74%	―	-60.16%	―
BRNS	46 Neutral	$44.38M	―	-53.78%	―	―	-5.42%
CLGN	44 Neutral	$33.32M	―	-78.25%	―	248.62%	26.22%
BOLD	40 Underperform	$25.74M	―	-42.65%	―	―	-10.95%
ALXO	39 Underperform	$56.76M	―	-104.21%	―	―	39.60%

Boundless Bio Inc. Corporate Events

Boundless Bio Shifts Focus and Restructures Leadership Team

Boundless Bio announced significant updates to its ecDNA-directed therapy programs and leadership team. The company has decided not to advance its BBI-825 program due to complex treatment landscapes and is focusing resources on BBI-355, with initial clinical data expected in 2025, and the third ecDTx program, aiming for a development candidate by mid-2025. Leadership changes include the departure of CMO Klaus Wagner and CBO Neil Abdollahian, with James L. Freddo stepping in as interim CMO. These strategic decisions extend the company’s operational funding into 2027, demonstrating a commitment to advancing its therapeutic pipeline and addressing unmet oncogene-amplified cancer needs.